{
  "id": 8866262,
  "title": "Moderna’s Bob Langer and AI pioneer Yann LeCun join board of Cellular Intelligence, bringing AI into medicine via a Parkinson’s drug",
  "url": "https://urgent.news/2026/09/21/modernas-bob-langer-and-ai-pioneer-yann-lecun-join-board-of-cellular",
  "topic": "ai",
  "section": "AI",
  "published": "2026-09-21T07:00:00.000Z",
  "source": {
    "name": "Fortune",
    "slug": "fortune",
    "url": "https://fortune.com/2026/09/21/moderna-bob-langer-ai-pioneer-yann-lecun-cellular-intelligence-board-ai-medicine/"
  },
  "original_language": "en",
  "account": "Moderna co-founder Robert \"Bob\" Langer and AI pioneer Yann LeCun have joined the scientific advisory board of Cellular Intelligence, a company aiming to predict and control living cell behavior using AI models. This move brings AI expertise into medicine, with the goal of accelerating drug development. Additionally, Jens Nielsen and Fabian Theis have joined Cellular Intelligence's board of directors, representing the Novo Nordisk Foundation’s BioInnovation Institute and the Computational Health Center at Helmholtz Munich, respectively. Cellular Intelligence, founded in 2023, aims to combine genomics, developmental biology, and AI to develop new medicines. The company has acquired the global rights to an experimental Parkinson's disease cell therapy, STEM-PD, which is currently in Phase 2 and carries FDA Fast Track designation.",
  "summary": "CI is pairing top AI and biotech minds on its board (plus an advisory role for OpenAI's Fidji Simo) as it tests models on a Novo Nordisk drug.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}